ISOactive
ISOactive, licence 80001570: inactive licence in Health Canada data. The French and European references below do not constitute authorisation for sale in France or an assessment of safety or efficacy.
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
Natural health product licensed in Canada
- Licence holder
- AHD International, LLC
- NPN or DIN-HM
- 80001570
- Status
- Inactive licence
- Licence date
- 5 April 2006
- Revision date
- Not provided
- Form
- Comprimé
- Route of administration
- Orale
- Application type
- Non traditionnelle
If this product were sold in France
No point flagged by the rules we apply.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
Medicinal composition not provided.
Non-medicinal ingredients
Anhydrous Microcrystalline Cellulose, Copolymère d'acide méthacrylique, Talc, Yellow tartrazine, triglycérides à chaînes moyennes, Granular Mannitol, Glyceryl Palmitostearate, Dioxyde de titane, Stéarate de magnésium, Dioxyde de silicium, Citrate de triéthyle, Glycolate d'amidon sodique, silice, Béhénate de glycéryle
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | Not specified | minimum: 1.0 Comprimé ; maximum: 4.0 Comprimé | 2.0 Tous les jours |
Uses authorised in Canada
Helps support a healthy mood balance . Helps to relieve osteoarthritic pain. Helps support healthy liver function.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Précautions et mises en garde
People who are taking anti-depressants, hepatoxic drugs or monoamine inhibitors should consult a health care practitioner before taking SAMe. Do not take at night since this product may cause anxiety, restlessness and insomnia. SAMe is not recommended for use in children.
- Contre-indications
People with bipolar disorder (manic-depressive illness) should not use SAMe unless under medical supervision. Do not use SAMe if pregnant or breastfeeding.
- Effets indésirables connus
Possible side effects are: mild gastrointestinal upsets (such as stomach pain, nausea, diarrhea, and flatulence), anxiety, hyperactive muscle movement, insomnia, and hypomania. When these side effects occur they often diminish with time or resolve with lower doses or cessation of use. There are no documented cases of allergies to SAMe.
Source
Official Health Canada record, licence 80001570
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.